Nerandomilast appears to reduce the risk of death in people with IPF and PPF, according to analyses of clinical trial data.

In her columns debut, Debbie Klein shares the story of her late husband Steve's idiopathic pulmonary fibrosis diagnosis.

LTI-03 was shown to reduce inflammation and scarring in lung tissue collected from IPF patients and analyzed in a lab, ...

Columnist Sam Kirton's diagnostic journey was relatively short compared with that of other idiopathic pulmonary fibrosis (IPF) patients.

For columnist Sam Kirton, Pulmonary Fibrosis Awareness Month is an opportunity to tell others about his journey.

GRI-0621, an experimental oral therapy for IPF, may stabilize lung function, according to an interim analysis of an ongoing ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

The National Institutes of Health has awarded $219,000 to fund a project at the University of Texas at Tyler aimed at developing a treatment for radiation-induced pulmonary fibrosis (PF) which can ...

Treatment with GRI Bio‘s investigational oral therapy GRI-0621 appears to reduce markers of fibrosis, or scarring, in people with idiopathic pulmonary fibrosis (IPF), according to an interim analysis ...

Besides medication that can help manage symptoms and slow the progression of pulmonary fibrosis (PF), there are other therapeutic strategies available that can help patients cope with the effects of ...

An experimental oral therapy for idiopathic pulmonary fibrosis (IPF) has been tolerated well in an ongoing Phase 2 clinical trial, according to interim data announced by its developer GRI Bio. “We are ...